THE WOODLANDS, Texas, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 13th Annual Jefferies London Healthcare Conference, taking place November 15-17, 2022.

Visit link:
Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference

Robust two-year X-ray results of medial joint space width (mJSW) and significant pain response in patients with earlier disease highlight the potential of lorecivivint to be a first-in-class, structure-modifying drug for the treatment of knee osteoarthritis Robust two-year X-ray results of medial joint space width (mJSW) and significant pain response in patients with earlier disease highlight the potential of lorecivivint to be a first-in-class, structure-modifying drug for the treatment of knee osteoarthritis

Follow this link:
Biosplice Announces Data from Recent Clinical Trials in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial

Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting

Read more here:
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting

Low-dose ICT01 plus low-dose IL-2 safely and significantly increase the number of activated ?9?2 T cells, CD8 T cells, and Natural Killer cells in patients with solid tumors

Continue reading here:
ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting

Three Lakes Foundation brings together academia, clinicians and industry to identify imaging insights for early detection of interstitial lung disease/pulmonary fibrosis (ILD/PF) Three Lakes Foundation brings together academia, clinicians and industry to identify imaging insights for early detection of interstitial lung disease/pulmonary fibrosis (ILD/PF)

Read this article:
Paving the way for better diagnosis, treatment and care in pulmonary fibrosis

COPENHAGEN, Denmark – November 11, 2022 - Bavarian Nordic A/S (OMX:  BAVA) today announced that Paul Chaplin, President & CEO will provide a corporate presentation at the Jefferies 2022 London Healthcare Conference on Thursday, November 17, 2022 at 8:35 am GMT (9:35 am CET).

Go here to read the rest:
Bavarian Nordic to Present at Jefferies 2022 London Healthcare Conference

NEEDHAM, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced presentation of late-breaking data from a phase 1 mechanistic clinical trial of CAN-2409, Candel’s lead viral immunotherapy in development, in combination with nivolumab and standard of care treatment in patients with high-grade glioma. Data were presented at the 37th Annual Meeting of Society for Immunotherapy of Cancer (SITC) today in Boston.

Go here to see the original:
Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1...

- Early signs of clinical activity were observed in patients receiving TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab; abscopal effect observed with monotherapy

Here is the original post:
Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors,...

WINSTON-SALEM, N.C., Nov. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will participate in the following upcoming investor conferences:

Link:
ProKidney to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.

Read more from the original source:
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia, Nov. 11, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the first quarter of fiscal year 2023, ended September 30, 2022.

The rest is here:
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update

CAMBRIDGE, Mass., Nov. 12, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced updated data from an ongoing Phase 1/2 clinical study of NTLA-2002 for the treatment of hereditary angioedema (HAE). The interim analyses were shared today in a Distinguished Industry Abstract oral presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific Meeting, being held November 10 – 14 in Louisville, Kentucky.

See original here:
Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the...

Entered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject to approval by Ayala’s shareholders and the satisfaction of customary closing conditions

See the article here:
Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase 1 study ALG-000184-201 Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase 1 study ALG-000184-201

Original post:
Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022

WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. is re-issuing its earnings press release for the third quarter ended September 30, 2022, issued on November 3, 2022 at 8:00 am ET, to correct and clarify certain information contained in the quotation of the Chief Executive Officer. All other information remains unchanged.

Read the rest here:
Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update

--Poster presentation to showcase NGM Bio’s in vitro and in vivo research supporting development of NGM936, a ILT3 x CD3 bispecific T cell engager product candidate engineered to direct T cell-mediated killing of ILT3-positive cancer cells----Oral presentation from the lab of Dr. Fabiana Perna at the Indiana University School of Medicine to showcase research done in collaboration with NGM Bio demonstrating the rationale for the study of NGM936 for the treatment of patients with multiple myeloma--

See the rest here:
NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting

NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced encouraging seladelpar data in patients with primary biliary cholangitis (PBC) that are being presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4th – 8th).

Read this article:
CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver...

Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points supports advancement into clinical studies

Here is the original post:
Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core...

Late-breaking abstract one of nine abstracts selected by SITC Communications Committee to be showcased at the SITC 2022 Press Conference

The rest is here:
Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference

Six-month outcomes are expected in second quarter of 2023 Six-month outcomes are expected in second quarter of 2023

See the rest here:
Osteal Therapeutics, Inc. Completes Enrollment in APEX Phase 2 Clinical Trial of VT-X7 for Periprosthetic Joint Infection